{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T12:37:30Z","timestamp":1770295050376,"version":"3.49.0"},"reference-count":44,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T00:00:00Z","timestamp":1743292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cutaneous metastatic melanoma (CMM) is the most aggressive form of skin cancer, with characteristics including a poor prognosis, chemotherapy-induced secondary tumorigenesis, and the emergence of drug resistance. Our recent study demonstrated that triphenyl phosphonium (TPP)-based nanovesicles (BPPB), which have amphiphilic properties, exert potent ROS-dependent anticancer effect against PLX4032 (PLX)-sensitive MeOV BRAFV600E and MeTRAV BRAFV600D mutant cell lines, evidencing more marked efficacy on MeOV cells. Here, taking advantage of this in vitro model, the antitumoral effect of BPPB was tested on PLX-resistant (PLX-R) MeOV BRAFV600E and MeTRAV BRAFV600D mutant cell lines to find a new potential strategy to fight melanoma therapy resistance. Specifically, we investigated both its effects on cell viability in dose- and time-dependent experiments and those on ROS generation. Our results show that BPPB exerted strong antiproliferative effects, regardless of their acquired resistance of cells to PLX, that correlated with ROS overproduction for 24 h treatments only. Moreover, in terms of cell viability, PLX-R MeTRAV cells demonstrated a remarkably higher tolerance to 24 h BPPB treatment than PLX-R MeOV. On the contrary, BPPB exposure for longer periods induced similar responses in both cell lines (IC50 = 87.8\u2013106.5 nM on MeOV and 81.0\u2013140.6 nM on MeTRAV). Notably, BPPB cytotoxicity on non-tumorigenic human keratinocytes (HaCaT) was low, thus establishing that BPPB is appreciably selective for CMM cells, allowing for selectivity index values (SIs) up to 11.58. Furthermore, the BPPB concentration causing 50% hemolysis (HC50) was found to be 16\u2013173 and 4\u2013192-fold higher than the IC50 calculated for PLX-R MeOV and MeTRAV cells, respectively. Correlation studies established that BPPB exerts cytotoxic effects on PLX-R MeOV and MeTRAV cells by a time-dependent mechanism, while a concentration-dependent mechanism was observed only at 24 h of exposure. Finally, a ROS-dependent mechanism can be assumed only in PLX-R MeTRAV cells in 72 h treatment.<\/jats:p>","DOI":"10.3390\/ijms26073227","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T03:25:02Z","timestamp":1743391502000},"page":"3227","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tri-Phenyl-Phosphonium-Based Nano Vesicles: A New In Vitro Nanomolar-Active Weapon to Eradicate PLX-Resistant Melanoma Cells"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4630-4371","authenticated-orcid":false,"given":"Silvana","family":"Alfei","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Genoa, Viale Cembrano, 16148 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2236-5142","authenticated-orcid":false,"given":"Carola","family":"Torazza","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Genoa, Viale Cembrano, 16148 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0686-7062","authenticated-orcid":false,"given":"Francesca","family":"Bacchetti","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Genoa, Viale Cembrano, 16148 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Grazia","family":"Signorello","sequence":"additional","affiliation":[{"name":"Biochemistry Laboratory, Department of Pharmacy, University of Genoa, Viale Benedetto XV 3, 16132 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2779-6259","authenticated-orcid":false,"given":"Mario","family":"Passalacqua","sequence":"additional","affiliation":[{"name":"Biochemistry Section, Department of Experimental Medicine (DIMES), University of Genova, Via Alberti L.B., 16132 Genoa, Italy"},{"name":"Centro 3R, Department of Information Engineering, University of Pisa, Largo Lucio Lazzarino 1, 56122 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5003-7333","authenticated-orcid":false,"given":"Cinzia","family":"Domenicotti","sequence":"additional","affiliation":[{"name":"Centro 3R, Department of Information Engineering, University of Pisa, Largo Lucio Lazzarino 1, 56122 Pisa, Italy"},{"name":"IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy"},{"name":"Department of Experimental Medicine (DIMES), University of Genova, Via Alberti L.B., 16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3056-6569","authenticated-orcid":false,"given":"Barbara","family":"Marengo","sequence":"additional","affiliation":[{"name":"Centro 3R, Department of Information Engineering, University of Pisa, Largo Lucio Lazzarino 1, 56122 Pisa, Italy"},{"name":"IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy"},{"name":"Department of Experimental Medicine (DIMES), University of Genova, Via Alberti L.B., 16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"(2012). Drugs in Clinical Development for Melanoma. Pharm. Med., 26, 171\u2013183.","DOI":"10.1007\/BF03262391"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0140-6736(23)00821-8","article-title":"Cutaneous Melanoma","volume":"402","author":"Long","year":"2023","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15003","DOI":"10.1038\/nrdp.2015.3","article-title":"Melanoma","volume":"1","author":"Schadendorf","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global Cancer Statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","unstructured":"Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2025, January 21). Global Cancer Observatory: Cancer Today International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.fr\/today\/en."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-pathol-012513-104658","article-title":"The Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia","volume":"9","author":"Bastian","year":"2014","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2021.09.044","article-title":"Cutaneous Melanoma Attributable to UVR Exposure in Denmark and Germany","volume":"159","author":"Keim","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3322\/caac.21440","article-title":"Proportion and Number of Cancer Cases and Deaths Attributable to Potentially Modifiable Risk Factors in the United States","volume":"68","author":"Islami","year":"2017","journal-title":"CA A Cancer J. Clin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2004.10.015","article-title":"Meta-Analysis of Risk Factors for Cutaneous Melanoma: I. Common and Atypical Naevi","volume":"41","author":"Gandini","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ijc.2910620402","article-title":"Risk of Cutaneous Melanoma Associated with Pigmentation Characteristics and Freckling: Systematic Overview of 10 Case-control Studies","volume":"62","author":"Bliss","year":"1995","journal-title":"Int. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.mayocp.2012.04.018","article-title":"Melanoma in Immunosuppressed Patients","volume":"87","author":"Kubica","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/jmg.2010.083022","article-title":"Cancer and Neurologic Degeneration in Xeroderma Pigmentosum: Long Term Follow-up Characterises the Role of DNA Repair","volume":"48","author":"Bradford","year":"2010","journal-title":"J. Med. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2105\/AJPH.2020.305567","article-title":"New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986\u20132016","volume":"110","author":"Stein","year":"2020","journal-title":"Am. J. Public Health"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1586\/era.10.170","article-title":"A New Understanding in the Epidemiology of Melanoma","volume":"10","author":"Erdei","year":"2010","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Leary, M., Heerboth, S., Lapinska, K., and Sarkar, S. (2018). Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy. Cancers, 10.","DOI":"10.3390\/cancers10120483"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF Gene in Human Cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrc3760","article-title":"Targeting RAF Kinases for Cancer Therapy: BRAF-Mutated Melanoma and Beyond","volume":"14","author":"Holderfield","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1158\/1078-0432.CCR-13-0898","article-title":"Molecular Pathways: BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation","volume":"20","author":"Haq","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical Efficacy of a RAF Inhibitor Needs Broad Target Blockade in BRAF-Mutant Melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/CMR.0000000000000398","article-title":"Vemurafenib Treatment for Patients with Locally Advanced, Unresectable Stage IIIC or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other than V600E","volume":"27","author":"Hallmeyer","year":"2017","journal-title":"Melanoma Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2147\/DDDT.S31143","article-title":"Vemurafenib: An Evidence-Based Review of Its Clinical Utility in the Treatment of Metastatic Melanoma","volume":"8","author":"Joseph","year":"2014","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Tanda, E.T., Vanni, I., Boutros, A., Andreotti, V., Bruno, W., Ghiorzo, P., and Spagnolo, F. (2020). Current State of Target Treatment in BRAF Mutated Melanoma. Front. Mol. Biosci., 7.","DOI":"10.3389\/fmolb.2020.00154"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Alfei, S., Zuccari, G., Bacchetti, F., Torazza, C., Milanese, M., Siciliano, C., Athanassopoulos, C.M., Piatti, G., and Schito, A.M. (2024). Synthesized Bis-Triphenyl Phosphonium-Based Nano Vesicles Have Potent and Selective Antibacterial Effects on Several Clinically Relevant Superbugs. Nanomaterials, 14.","DOI":"10.20944\/preprints202407.0891.v1"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Alfei, S., Zuccari, G., Athanassopoulos, C.M., Domenicotti, C., and Marengo, B. (2024). Strongly ROS-Correlated, Time-Dependent, and Selective Antiproliferative Effects of Synthesized Nano Vesicles on BRAF Mutant Melanoma Cells and Their Hyaluronic Acid-Based Hydrogel Formulation. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202409.0607.v1"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Alfei, S., Giannoni, P., Signorello, M.G., Torazza, C., Zuccari, G., Athanassopoulos, C.M., Domenicotti, C., and Marengo, B. (2024). The Remarkable and Selective In Vitro Cytotoxicity of Synthesized Bola-Amphiphilic Nanovesicles on Etoposide-Sensitive and -Resistant Neuroblastoma Cells. Nanomaterials, 14.","DOI":"10.20944\/preprints202408.0465.v1"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Garbarino, O., Valenti, G.E., Monteleone, L., Pietra, G., Mingari, M.C., Benzi, A., Bruzzone, S., Ravera, S., Leardi, R., and Farinini, E. (2023). PLX4032 Resistance of Patient-Derived Melanoma Cells: Crucial Role of Oxidative Metabolism. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1210130"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.progpolymsci.2012.09.003","article-title":"Bolaamphiphilic Molecules: Assembly and Applications","volume":"38","author":"Nuraje","year":"2013","journal-title":"Prog. Polym. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1801688","DOI":"10.1002\/advs.201801688","article-title":"Targeted Therapy against Metastatic Melanoma Based on Self-Assembled Metal-Phenolic Nanocomplexes Comprised of Green Tea Catechin","volume":"6","author":"Li","year":"2019","journal-title":"Adv. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/bimj.19620040313","article-title":"Steel, R. G. D., and J. H. Torrie: Principles and Procedures of Statistics. (With Special Reference to the Biological Sciences.) McGraw-Hill Book Company, New York, Toronto, London 1960, 481 S., 15 Abb.; 81 s 6 d","volume":"4","author":"Heinisch","year":"1962","journal-title":"Biom. Z"},{"key":"ref_30","unstructured":"Bobbitt, Z. (2025, January 22). What Is a Good R-Squared Value?. Available online: https:\/\/www.statology.org\/good-r-squared-value\/#:~:text=For%20example%2C%20in%20scientific%20studies%2C%20the%20R-squared%20may,if%20there%20is%20extreme%20variability%20in%20the%20dataset."},{"key":"ref_31","unstructured":"(2025, January 22). Valutazione Della Bont\u00e0 Di Adattamento per Modelli Non Lineari: Metodi, Parametri e Considerazioni Pratiche. Available online: https:\/\/www.geeksforgeeks.org\/evaluating-goodness-of-fit-for-nonlinear-models-methods-metrics-and-practical-considerations\/."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jcis.2018.07.067","article-title":"Aggregation Behaviour of Triphenylphosphonium Bolaamphiphiles","volume":"531","author":"Ceccacci","year":"2018","journal-title":"J. Colloid Interface Sci."},{"key":"ref_33","first-page":"1","article-title":"Repurposing FDA-Approved Compounds to Target JAK2 for Colon Cancer Treatment","volume":"15","author":"Chandrasekhar","year":"2024","journal-title":"Discov. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1083\/jcb.106.3.761","article-title":"Normal Keratinization in a Spontaneously Immortalized Aneuploid Human Keratinocyte Cell Line","volume":"106","author":"Boukamp","year":"1988","journal-title":"J. Cell Biol."},{"key":"ref_35","first-page":"146","article-title":"Comparison of Primary Human Fibroblasts and Keratinocytes with Immortalized Cell Lines Regarding Their Sensitivity to Sodium Dodecyl Sulfate in a Neutral Red Uptake Cytotoxicity Assay","volume":"59","author":"Schrader","year":"2009","journal-title":"Arzneimittelforschung"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1523-1747.1999.00524.x","article-title":"Epidermal Organization and Differentiation of HaCaT Keratinocytes in Organotypic Coculture with Human Dermal Fibroblasts","volume":"112","author":"Schoop","year":"1999","journal-title":"J. Investig. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.tiv.2009.09.014","article-title":"In Vitro Mammalian Cytotoxicological Study of PAMAM Dendrimers \u2014 Towards Quantitative Structure Activity Relationships","volume":"24","author":"Mukherjee","year":"2010","journal-title":"Toxicol. Vitr."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Krzywik, J., Mozga, W., Aminpour, M., Janczak, J., Maj, E., Wietrzyk, J., Tuszy\u0144ski, J.A., and Huczy\u0144ski, A. (2020). Synthesis, Antiproliferative Activity and Molecular Docking Studies of Novel Doubly Modified Colchicine Amides and Sulfonamides as Anticancer Agents. Molecules, 25.","DOI":"10.3390\/molecules25081789"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1021\/acs.jnatprod.7b00578","article-title":"Cytotoxicity, Hemolytic Toxicity, and Mechanism of Action of Pulsatilla Saponin D and Its Synthetic Derivatives","volume":"81","author":"Chen","year":"2017","journal-title":"J. Nat. Prod."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Wr\u00f3blewska-\u0141uczka, P., Kulenty, L., Za\u0142uska-Ogryzek, K., G\u00f3ralczyk, A., and \u0141uszczki, J.J. (2025). Screening of the Antimelanoma Activity of Monoterpenes\u2014In Vitro Experiments on Four Human Melanoma Lines. Curr. Issues Mol. Biol., 47.","DOI":"10.3390\/cimb47020097"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Alfei, S., Marengo, B., and Domenicotti, C. (2020). Polyester-Based Dendrimer Nanoparticles Combined with Etoposide Have an Improved Cytotoxic and Pro-Oxidant Effect on Human Neuroblastoma Cells. Antioxidants, 9.","DOI":"10.3390\/antiox9010050"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Alfei, S., Marengo, B., Zuccari, G., Turrini, F., and Domenicotti, C. (2020). Dendrimer Nanodevices and Gallic Acid as Novel Strategies to Fight Chemoresistance in Neuroblastoma Cells. Nanomaterials, 10.","DOI":"10.3390\/nano10061243"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"70715","DOI":"10.18632\/oncotarget.12209","article-title":"Glutathione-Mediated Antioxidant Response and Aerobic Metabolism: Two Crucial Factors Involved in Determining the Multi-Drug Resistance of High-Risk Neuroblastoma","volume":"7","author":"Colla","year":"2016","journal-title":"Oncotarget"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/B978-0-12-416618-9.00013-3","article-title":"Methods to Monitor ROS Production by Fluorescence Microscopy and Fluorometry","volume":"542","author":"Wojtala","year":"2014","journal-title":"Methods Enzymol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/7\/3227\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:06:12Z","timestamp":1760029572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/7\/3227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,30]]},"references-count":44,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["ijms26073227"],"URL":"https:\/\/doi.org\/10.3390\/ijms26073227","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,30]]}}}